Tempest Therapeutics Inc

Tempest Therapeutics, Inc. is a clinical-stage biotechnology company that develops small molecule therapeutics for cancer. Its lead candidates are Amezalpat, an oral selective PPAR alpha antagonist that completed a Phase 2 trial for first-line unresectable or metastatic hepatocellular carcinoma, and TPST-1495, a dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for various cancers. The company has a collaboration with F. Hoffmann-La Roche Ltd. for a global first-line randomized study of Amezalpat, and a product development and investigator-initiated trial collaboration with Heibei Senlang Biotechnology Co., Ltd. for TPST-4003. It is headquartered in Brisbane, California.